Identification of Hub Diagnostic Biomarkers and Candidate Therapeutic Drugs in Heart Failure

Abstract

Purpose The objective of this study was to identify the potential regulatory mechanisms, diagnostic biomarkers, and therapeutic drugs for heart failure (HF). Methods Differentially expressed genes (DEGs) between HF and non-failing donors were screened from the GSE57345, GSE5406, and GSE3586 datasets. Database for Annotation Visualization and Integrated Discovery and Metascape were used for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses respectively. The GSE57345 dataset was used for weighted gene co-expression network analysis (WGCNA). The intersecting hub genes from the DEGs and WGCNA were identified and verified with the GSE5406 and GSE3586 datasets. The diagnostic value of the hub genes was calculated through receiver operating characteristic analysis and net reclassification index (NRI). Gene set enrichment analysis (GSEA) was used to filter out the signaling pathways associated with the hub genes. SYBYL 2.1 was used for molecular docking of hub targets and potential HF drugs obtained from the connection map. Results Functional annotation of the DEGs showed enrichment of negative regulation of angiogenesis, endoplasmic reticulum stress response, and heart development. PTN, LUM, ISLR, and ASPN were identified as the hub genes of HF. GSEA showed that the key genes were related to the transforming growth factor-β (TGF-β) and Wnt signaling pathways. Sirolimus, LY-294002, and wortmannin have been confirmed as potential drugs for HF. Conclusion We identified new hub genes and candidate therapeutic drugs for HF, which are potential diagnostic, therapeutic and prognostic targets and warrant further investigation.

Identification of potential biomarkers of inflammation-related genes for ischemic cardiomyopathy

“…There is a trend that multiple ML algorithms such as least absolute shrinkage and selection operator (LASSO), support vector machine recursive feature elimination (SVM-RFE), random forest (RF) are used to screen disease biomarkers and therapeutic targets, explore pathogenesis and predict clinical outcomes, which will allow for more rigorous and standardized processes. Many studies have also attempted to explore the possible pathological progression mechanisms of ICM by combining data from the public database, bioinformatics analysis, and ML algorithms (13)(14)(15). However, few studies have been conducted to identify potential inflammation-related diagnostic genes for ICM.…”

Highly Accessible Computational Prediction and In Vivo/In Vitro Experimental Validation: Novel Synthetic Phenyl Ketone Derivatives as Promising Agents against NAFLD via Modulating Oxidoreductase Activity

“…A higher total score suggests a closer interaction between drug and potential target. When total score is ≥4, the drug is considered a candidate to be studied continuously [ 45 ]. The obtained total scores of compound 5f with nineteen DEPs were indicated with filled triangles in Figure 6(b) , and all of them were larger than 4.…”

“…Green solid. Yield: 45 supplemented with 10% fetal bovine serum (Minhai, China) and 1% penicillin/streptomycin at 37 °C and 5% CO 2 . After growing HepG2 cells overnight, the cells were treated with 500 μM PA (Solarbio, China) for 24 h. For pharmacological treatments, HepG2 cells were treated with different concentrations of compound 5f simultaneously.…”

A systematic study of traditional Chinese medicine treating hepatitis B virus-related hepatocellular carcinoma based on target-driven reverse network pharmacology

“…A higher total score suggests a closer interaction between small molecule and potential target ( Li et al., 2022 ; Zhang et al, 2019 ). A total score ≥ 4.0 indicates that the small molecule binds well to the targets ( Guo et al., 2022 ). Considering that 3D structure for CAV1 was not available in the PDB database, docking studies were performed between 46 targets and the top 50 chemical components ranked by node degree value.…”